Global Genomics In Cancer Care Market Size, Share & Trends Analysis Report By Application, By Product (Instruments, Consumables, Services), By Technology, By Regional Outlook and Forecast, 2024 - 2031

Global Genomics In Cancer Care Market Size, Share & Trends Analysis Report By Application, By Product (Instruments, Consumables, Services), By Technology, By Regional Outlook and Forecast, 2024 - 2031

The Global Genomics In Cancer Care Market size is expected to reach $53.5 billion by 2031, rising at a market growth of 15.7% CAGR during the forecast period.

High-throughput capabilities are provided by microarrays, which allow for the simultaneous analysis of thousands of transcripts in a single experiment. This extensive data collection is crucial for understanding cancer’s complex genetic and molecular landscapes, leading to increased demand for microarray technologies in research and clinical applications. Microarrays enable comprehensive gene expression profiling, which helps identify differentially expressed cancer-associated genes. By providing a broad overview of gene activity, microarrays support discovering biomarkers, elucidating cancer mechanisms, and developing new therapeutic targets. Thus, the microarrays segment held 21% revenue share in the genomics in cancer care market.

The major strategies followed by the market participants are Acquisition as the key developmental strategy to keep pace with the changing demands of end users. For instance, In 2023, January, Agilent Technologies acquired Avida Biomed, a cancer care solutions provider. The acquisition enhances its SureSelect portfolio with advanced target enrichment workflows for next-generation sequencing. Additionally, In 2021, June, PerkinElmer, now known as Revvity, Inc., took over Sirion Biotech, a German biotech company. The acquisition enhances Perkinelmer's cell and gene therapy offerings.

Based on the Analysis presented in the KBV Cardinal matrix; F. Hoffmann-La Roche Ltd. is the forerunners in the Genomics In Cancer Care Market. Companies such as Abbott Laboratories, Danaher Corporation (Beckman Coulter, Inc.), GE HealthCare Technologies, Inc. are some of the key innovators in Genomics In Cancer Care Market.

COVID-19 Impact Analysis

Budget cuts and reallocating funds towards COVID-19 response efforts resulted in reduced investment in genomic research and development. Many clinical trials for genomic-based cancer therapies were paused or delayed during the pandemic. Recruitment of participants was hindered, and trial timelines were extended, affecting the development and availability of new genomic treatments. Thus, the COVID-19 pandemic had a negative impact on the market.

Market Growth Factors

A better grasp of cancer genomics allows for developing personalized medicine approaches. By analyzing a patient’s unique genetic makeup, healthcare providers can tailor treatment plans specifically to the individual’s cancer type and genetic profile. This personalized approach improves treatment efficacy and minimizes adverse effects, leading to a growing demand for genomic-based treatments.

Additionally, the increased focus on genomic research drives market growth by fostering the development of new genomic technologies and therapies. Thus, the rise in cancer incidence and prevalence is driving the growth of the market.

Market Restraining Factors

High costs of genomic testing can exacerbate disparities in healthcare access, particularly in low- and middle-income regions or among underserved populations. These disparities can result in unequal access to advanced genomic technologies and personalized treatments, affecting the overall market growth and hindering equitable cancer care. Hence, the high costs of genomic testing impede the market’s growth.

Application Outlook

On the basis of application, the market is segmented into diagnostics, personalized medicine, drug discovery & development, and research. The diagnostics segment recorded 39% revenue share in the genomics in cancer care market in 2023. Genomic diagnostics are crucial in early detection and accurate cancer diagnosis.

Product Outlook

Based on product, the market is divided into instruments, consumables, and services. The services segment attained 21% revenue share in the genomics in cancer care market in 2023. As genomic technologies advance, the complexity of analyzing and interpreting genomic data increases.

Technology Outlook

By technology, the market is divided into genome sequencing, PCR, microarrays, nuclei acid extraction and purification, and others. In 2023, the PCR segment registered 32% revenue share in the genomics in cancer care market. PCR is known for its high sensitivity and specificity, which are crucial for accurately detecting and quantifying cancer-related genetic material.

By Regional Analysis

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2023, the Asia Pacific region generated 26% revenue share in the genomics in cancer care market. The Asia-Pacific region is experiencing a rising incidence of cancer due to factors such as population growth, aging demographics, and changes in lifestyle and environmental exposures.

Market Competition and Attributes

The Genomics in Cancer Care market is fiercely competitive, driven by rapid technological advancements and the increasing demand for personalized medicine. Key attributes include innovative genomic testing techniques, comprehensive data analytics capabilities, and robust bioinformatics solutions. Companies strive to differentiate through superior accuracy in cancer diagnostics, treatment selection, and monitoring. Market leaders focus on integrating multi-omic data to enhance therapeutic outcomes, while regulatory compliance and data privacy remain critical concerns.

Recent Strategies Deployed in the Market

• Aug-2024: Beckman Coulter Life Sciences released the Illumina TruSight Oncology 500 DNA/RNA assa, an automated solution for oncology research on the Biomek NGeniuS System. This tool accelerates genomic profiling of tumor samples, handling up to 24 libraries per batch with reduced costs and faster results.
• Apr-2024: Bio-Rad Laboratories partnered with Allegheny Health Network to research the use of Bio-Rad’s Droplet Digital PCR (ddPCR) technology for monitoring molecular residual disease (MRD) in solid tumors. This partnership would enhance sensitivity and precision in detecting MRD, potentially improving patient outcomes through earlier and more accurate monitoring.
• Apr-2024: Bio-Rad Laboratories released the ddPLEX ESR1 Mutation Detection Kit, a highly sensitive multiplexed digital PCR assay for detecting seven ESR1 mutations with 0.01% sensitivity. Compatible with the QX600 System, it provides rapid, simultaneous results from ctDNA or FFPE samples, enhancing oncology research and patient monitoring.
• Oc-2023: F. Hoffmann-La Roche Ltd teamed up with AWS, a cloud computing company, to integrate AI-powered tools into its navify Digital Pathology platform. This partnership enhanced breast and prostate cancer diagnosis by improving accuracy, efficiency, and turnaround time in pathology labs, leveraging cloud infrastructure for scalability and security.

List of Key Companies Profiled

• Agilent Technologies, Inc.
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation (Beckman Coulter, Inc.)
• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• GE HealthCare Technologies, Inc.
• Quest Diagnostics Incorporated
• Revvity, Inc.
• Eurofins Scientific SE
• Hologic, Inc.

Global Genomics In Cancer Care Market Report Segmentation

By Application

• Diagnostics
• Personalized Medicine
• Drug Discovery & Development
• Research

By Product

• Instruments
• Consumables
• Services

By Technology

• PCR
• Genome Sequencing
• Microarrays
• Nuclei Acid Extraction & Purification
• Others

By Geography

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific
• LAMEA
• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA